Sivextro (tedizolid) is a small molecule pharmaceutical. Tedizolid was first approved as Sivextro on 2014-06-20. It is used to treat bacterial infections, bacterial skin diseases, staphylococcal infections, and streptococcal infections in the USA. It has been approved in Europe to treat bacterial skin diseases and soft tissue infections. Sivextro's patents are valid until 2030-12-31 (FDA).
|Indication||bacterial infections, bacterial skin diseases, soft tissue infections, staphylococcal infections, streptococcal infections|
|Drug Class||Oxazolidinone antibacterials|